Table 2.

Associations of Body Mass Index and Waist-to-hip Ratio With Total and Relapse/disease-specific Mortality

	Total mortality				Relapse/disease-specific mortality
	No. of subjects (n=5042)	No. of events (n=442)	Adjusted		No. of subjects (n=4989)	No. of events (n=481)	Adjusted
			HR	95% CI			HR	95% CI
BMI 1-year before diagnosisa
<18.5	180	18	1.44	0.88, 2.37	174	17	1.18	0.71, 1.96
18.5–24.9	3198	253		1.00	3176	281		1.00
25.0–29.9	1400	126	1.02	0.81, 1.27	1381	143	1.08	0.88, 1.34
≥30.0	264	45	1.58	1.13, 2.22	258	40	1.39	0.98, 1.97
BMI at diagnosisa
<18.5	207	22	1.45	0.92, 2.28	203	21	1.21	0.76, 1.91
18.5–24.9	3238	258		1.00	3213	284		1.00
25.0–29.9	1341	118	0.99	0.79, 1.24	1323	135	1.06	0.86, 1.31
≥30.0	256	44	1.55	1.10, 2.17	250	41	1.44	1.02, 2.03
BMI at 6 months post-diagnosisa
< 18.5	149	11	0.95	0.51, 1.74	148	13	1.01	0.57, 1.77
18.5–24.9	3112	255		1.00	3088	270		1.00
25.0–29.9	1498	136	0.97	0.78, 1.20	1473	151	1.06	0.87, 1.30
≥30.0	283	40	1.33	0.94, 1.87	280	47	1.49	1.08, 2.06
WHR (quartile)b
<0.796	1261	98		1.00	1252	105		1.00
0.796–0.832	1261	83	0.78	0.58, 1.05	1253	105	0.96	0.72, 1.27
0.833–0.869	1248	109	0.97	0.73, 1.30	1234	120	1.00	0.76, 1.33
≥0.870	1272	152	1.22	0.91, 1.63	1250	151	1.17	0.88, 1.56
P value for trend			0.057				0.226

Abbreviations: HR, hazard ratio; BMI, body mass index; WHR, waist-to-hip ratio.

^aAdjusted for age at diagnosis, education, income, marital status, comorbidity, exercise participation, intake of meats, cruciferous vegetable, and soy protein, time interval from diagnosis to study enrollment, menopausal status, menopausal symptoms, surgery, chemotherapy, radiotherapy, immunotherapy, tamoxifen use, tumor-node metastasis stage, and estrogen/progesterone receptor status.

^bFurther adjusted for BMI at 6 months post-diagnosis.